Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
ImmunoOncology Cancer Clinical Trials

Nektar's IL-2 Impresses In Combination With Bristol's Opdivo

Executive Summary

Nektar's IL-2 stimulating agonist NKTR-214 combines well with Bristol's Opdivo in Phase I PIVOT-02 study presented at SITC meeting in November.

You may also be interested in...



Keeping Track: Turalio, Nubeqa And Accrufer Mark Trio Of Novel Drug Approvals

The latest drug development news and highlights from our US FDA Performance Tracker.

Nektar/Bristol Deal May Shake Up Immuno-Oncology Landscape

The multibillion-dollar collaboration includes 20 studies, including two pivotal trials in renal cell carcinoma and non-small cell lung cancer that will start in the middle of the year.

Bristol Goes In Big On New Valentine Nektar

Bristol paid a handsome $1.85bn upfront for access to Nektar's lead immuno-oncology program NKTR-214 to study in combination with its own drugs, but the expense was viewed by some as a smart play versus buying Nektar outright.

Table

View full table

Related Content

In Vivo
Scrip

Topics

Related Companies

Tags:
ImmunoOncology Cancer Clinical Trials
Latest Headlines

Metsera Launches As New Obesity Contender Flush With $290m

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

See All
UsernamePublicRestriction

Register

SC099882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By